Roche Signs $1.7 Billion Deal with Blueprint Medicines to Develop Cancer Treatment

Roche has signed a $1.7 billion agreement with Blueprint Medicines to develop and commercialize Blueprint’s pralesetinib for treatment of patients with RET-altered cancers.

Blueprint and Roche’s subsidiary Genentech will co-commercialize pralsetinib in the U.S., while Roche will have exclusive rights to the drug outside of the U.S., except for China.

Blueprint will receive $775 million in upfront payments, and is eligible to receive up to $926 million in potential milestones, as well as royalties on sales outside of the U.S.